Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: 14 | Rare Historical Photos

The latest COVID booster will soon be available. Should I get one? Am I eligible?

Australia’s Therapeutic Goods Administration (TGA) has recently approved a new COVID booster. The shot was developed by Pfizer and targets the JN.1 sub-variant of Omicron.

The Conversation

ORIC: Working with Two Pharma Giants, Analysts See +100% Upside

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.

MarketBeat

Thursday's Unusual Options Activity Reveals 3 Promising Long-Term Investments

Thursday's trading session revealed 33 call options with unusually high activity and boasting expiration dates of 365 days or more. Three have emerged as promising long-term investments from this diverse pool of potential opportunities.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Reasons to be hopeful: five ways science is making the world better

If Trump’s re-election is getting you down, these innovations in medicine and technology should cheer you up

The Guardian - UK

Don't wait for a holiday surge. Now is a good time to get your flu and COVID-19 vaccines

Health officials say it's important to get flu and COVID-19 vaccines ahead of the holidays when respiratory bugs tend to spread

The Independent UK

Is This High-Yield Dividend Stock a Buy After Earnings?

This pharmaceutical giant's Q3 numbers came in ahead of Street estimates.

Barchart

Are Wall Street Analysts Predicting Pfizer Stock Will Climb or Sink?

Despite Pfizer’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Stock Market Today: Nasdaq Hits New High Ahead of Alphabet Earnings

The Google parent is one of several mega caps reporting earnings this week, with results due out after Tuesday's close.

Kiplinger

Why Pfizer Stock Is Lower After a Beat-and-Raise Quarter

Pfizer stock is down Tuesday even after the drugmaker reported higher-than-expected Q3 earnings and raised its full-year outlook.

Kiplinger

Hundreds of blood cancer patients to benefit from new Pfizer treatment

Myeloma affects 24,000 people a year in the UK

The Independent UK

Stock Index Futures Tread Water Ahead of U.S. JOLTs Report, Alphabet Earnings on Tap

December S&P 500 E-Mini futures (ESZ24) are up +0.06%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.08% this morning as market participants geared up for the latest reading on U.S. job openings while also awaiting a deluge of corporate earnings reports from heavyweight names.

Barchart

Gold price hits fresh record high, as bitcoin also rallies – as it happened

Analysts say gold is benefited from safe-haven demand amid persistent geopolitical tensions, expectations of monetary policy easing, and mounting uncertainty surrounding the US presidential election.

The Guardian - UK

As activist Starboard engages constructively, here’s a potent prescription for Pfizer’s future success under Dr. Bourla’s watch

Pfizer is getting back on track—but an even more potent prescription for success could be in the cards for the pharmaceutical giant under.

Fortune

What to Expect From Pfizer's Q3 2024 Earnings Report

Pfizer is expected to release its fiscal third-quarter earnings later this month, and analysts project a triple-digit profit growth.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Should You Follow Activist Investors Into This High-Yield Dividend Stock?

This dividend stock is now on the radar of activist investors, with Starboard eyeing a possible management shakeup.

The Guardian - UK

‘The UK is at the back of the race of turtles’: Sanofi’s boss on the need to develop new medicines

Paul Hudson, the Briton in charge of the French drug firm, is a big believer in the potential of AI to transform healthcare

Barchart

How To Spot Good Value Stocks In A Sea Of Noise

Explore why traditional value investing often falls short and how catalysts can transform undervalued stocks into lucrative investments.

Fortune

Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis

'Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff Sonnenfeld and Steven Tian.

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

Stock Market Today: Markets Slip on Hot Inflation Print, Layoff News

Economic data continues to complicate expectations for Federal Reserve rate cuts.

Barchart

3 High-Yield Stocks for Growing Dividend Income

Each of these companies boasts a solid track record of paying and raising dividends, with yields exceeding 5%.

Barchart

Is This Overlooked Dividend Stock Yielding Almost 6% a Good Turnaround Play?

Despite its dividend yield of nearly 6%, Pfizer stock has failed to win over investors and is in the red YTD. Can the stock finally stage a turnaround, as activist investor Starboard Value has reportedly taken a stake in the company?

Barchart

2 Covered Call Ideas on Pfizer Stock

Today, we’re looking at two covered call examples on Pfizer stock. The first step to finding our covered call candidates is to use the Stock Scanner with the following parameters:

The Conversation

One of science’s greatest achievements: how the rapid development of COVID vaccines prepares us for future pandemics

Since COVID was first reported in December 2019, there have been more than 775 million recorded infections and more than 7 million deaths from the disease. This makes COVID the seventh-deadliest pandemic in recorded history.

Fortune

Pfizer stock surges after activist takes $1 billion stake

The drugmaker has shed nearly $180 billion in market cap after struggling to chart a new course as the COVID-19 pandemic waned.

International Business Times

Activist Starboard Takes $1 Billion Stake In Pfizer, Seeks Former Execs' Support: Reports

Starboard has reached out to former Pfizer CEO Ian Read and ex-finance chief Frank D'Amelio, and both have expressed interest in supporting the activist investor's turnaround efforts, reports said.

1 … 13 14 15 16

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.